MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
13.62
+0.56
+4.29%
Opening 09:57 04/01 EDT
OPEN
13.09
PREV CLOSE
13.06
HIGH
13.73
LOW
12.88
VOLUME
11.19K
TURNOVER
--
52 WEEK HIGH
16.33
52 WEEK LOW
3.350
MARKET CAP
508.52M
P/E (TTM)
-6.2904
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTNM last week (0323-0327)?
Weekly Report · 2d ago
Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth
Simply Wall St · 5d ago
Weekly Report: what happened at CTNM last week (0316-0320)?
Weekly Report · 03/23 10:34
Weekly Report: what happened at CTNM last week (0309-0313)?
Weekly Report · 03/16 10:33
Contineum Therapeutics grants 51,000-share inducement stock option under 2026 employment plan
Reuters · 03/13 20:05
CONTINEUM THERAPEUTICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 03/13 20:05
Morgan Stanley Reaffirms Their Hold Rating on Contineum Therapeutics, Inc. Class A (CTNM)
TipRanks · 03/10 10:45
Weekly Report: what happened at CTNM last week (0302-0306)?
Weekly Report · 03/09 10:34
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.